Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes-So Why Is Their Uptake So Low?
Aaron KingEden M MillerPublished in: Clinical diabetes : a publication of the American Diabetes Association (2023)
A target A1C of <7% is the recommended goal for most people with type 2 diabetes. However, many are not achieving this target with their current treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are highly efficacious in achieving glycemic control and could aid primary care providers (PCPs) in getting patients to their A1C target. However, despite their potential, use of GLP-1 receptor agonists in the primary care setting is limited. This review provides guidance for PCPs on how to help patients achieve their glycemic target and overcome perceived barriers of GLP-1 receptor agonist use, with the overall goal of improving PCP confidence in prescribing these agents.
Keyphrases
- primary care
- type diabetes
- glycemic control
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- physical activity
- prognostic factors
- depressive symptoms
- emergency department
- metabolic syndrome
- patient reported outcomes
- cardiovascular disease
- mental health
- blood glucose
- risk assessment
- patient reported